On October 6, 2022, AIM Vaccine Corporation (" AIM ", stock code: 06660.HK) made its initial public offering and went public on the Main Board of the Hong Kong Stock Exchange.

Its vaccine business covers the entire industry value chain from research and development to manufacturing and commercialization. After years of development, AIM has established its position as a leading enterprise in the domestic vaccine industry.

The listed by Goldman Sachs, CICC, China Securities (International) Brokerage Company Limited, Macquarie Group Limited as co-sponsors.

Sullivan & Cromwell LLP and Jingtian & Gongcheng LLP acted as the Hong Kong and U.S. legal counsel and China legal counsel for the issuer.

Latham & Watkins and Junhe LLP act as the legal counsel in Hong Kong and the United States, and the legal counsel in China for the underwriters.

Ernst & Young provides audit services.

China Insights Consultancy is acting as industry consultant.